Mirati Therapeutics secures UK approval for KRAZATI in advanced NSCLC

Mirati Therapeutics, Inc. (NASDAQ: MRTX), an innovative biotechnology company, has received conditional authorization from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for its ... Read More